GO
Loading...

Enter multiple symbols separated by commas

Stocks Merck & Co Inc

More

  • Questions Arise Again on Vytorin Cancer Risk Tuesday, 2 Sep 2008 | 5:03 AM ET

    Two reports and an editorial in "The New England Journal of Medicine" are raising questions again about the potentially higher risk of death from cancer associated with a popular cholesterol-fighting drug.

  • For Widely Used Drug, Question of Usefulness Lingers Tuesday, 2 Sep 2008 | 4:51 AM ET
    PFIZER.jpg

    When the Food and Drug Administration approved a new type of cholesterol-lowering medicine in 2002, it did so on the basis of a handful of clinical trials covering a total of 3,900 patients. None of the patients took the medicine for more than 12 weeks, and the trials offered no evidence that it had reduced heart attacks or cardiovascular disease, the goal of any cholesterol drug, the New Yor Times reported.

  • Hurricane Lurking For Merck & Schering-Plough? Friday, 29 Aug 2008 | 11:34 AM ET
    vytorin_logo.jpg

    This won't be much of an end-of-summer holiday weekend for the folks at Merck and Schering-Plough. That's because early Tuesday morning (5am ET) the detailed results of the so-called SEAS study will be presented at a scientific conference in Germany. This is the test of MRK and SGP's cholesterol drug Vytorin, which showed a higher incidence of cancer among the patients taking the pill.

  • Merck's Charm Offensive Thursday, 28 Aug 2008 | 10:49 AM ET
    Gardasil Advertisment

    In the current monster-sized issue of Vogue, my producer, Ruth, while killing time on the Delta shuttle on our way from New York to Boston for a shoot this week, uncovered a blogworthy story buried in the hundreds and hundreds and hundreds of pages of fashion ads. It represents a whole new idea in the world of direct-to-consumer (DTC) drug advertising.

  • Do the markets prefer Republicans? Tuesday, 26 Aug 2008 | 7:31 AM ET
    080826 Obama McCain.jpg

    With the Democratic National Convention starting yesterday, the conversation over which candidate will be better for the economy will heat up.  Here are some stats on the Dow and presidential elections. With the exception of FDR's takeover for Herbert Hoover, it looks like "Change" seems to be less favorable to the markets than continuity when a Republican is in office. The best year for the Dow, on the other hand, occurred under a Democrat's administration.

  • Merck Drug Gets Mixed Review from Medical Journal Wednesday, 20 Aug 2008 | 5:03 PM ET
    Gardasil.jpg

    Two prominent articles in a major medical journal are examining the cost benefits and safety of an expensive, controversial vaccine for a sexually-transmitted disease and cancer.

  • Best Trades Now: Healthcare, Growth Stocks & More Monday, 18 Aug 2008 | 1:42 PM ET

    To give investors an edge, CNBC asked the experts for their best trades now.

  • Abbott's Covering The Bases Thursday, 14 Aug 2008 | 1:28 PM ET

    The market cap of Dow component Johnson & Johnson is a whopping $200 billion. Abbott Labs is valued at less than half that. But think of ABT as kind of a mini-me JNJ because like Johnson & Johnson, ABT has cobbled together a similar three-siloed business of drugs, devices and consumer products.

  • Stocks Close Lower But Pare Some Losses Wednesday, 13 Aug 2008 | 3:01 PM ET

    Stocks closed lower, hurt by rising oil prices and fresh worries about the financial sector, though the market ended off its lows for the day.

  • Stocks Suffer as Retail Slips, Deere Misses Wednesday, 13 Aug 2008 | 9:47 AM ET

    Stocks opened lower amid signs that the consumer was buying fewer goods that will cost more in the future.

  • Elan On Eight-Eight-Oh-Eight, Etc. Friday, 8 Aug 2008 | 11:47 AM ET
    Elan

    The Elanians have been pretty quiet in the wake of last week's bad news. and the stock getting about a two-thirds haircut. And I don't mean to rub salt in the wound.

  • Lightning Round OT: Merck, First Solar and More Monday, 28 Jul 2008 | 7:16 PM ET

    The Lightning Round is extended in this CNBC.com exclusive feature.

  • Dow Loses 1.1% for Week as Banks Skid Friday, 25 Jul 2008 | 6:05 PM ET

    Stocks pulled off modest gains Friday as enthusiasm for some better-than-expected economic reports outshined a warning from S&P of a possible downgrade on Fannie Mae and Freddie Mac.

  • Quick Market Stats: Week of 7/21 Friday, 25 Jul 2008 | 5:24 PM ET

    On a heavy earnings week with over 30% of the S&P 500 reporting, the markets end the week mixed on positive economic data and a decline in oil prices to an almost two-month low.  The Dow and S&P are both down for the week while the NASDAQ ends the week up about 1.2%. 

  • The State of Statins & Stents Friday, 25 Jul 2008 | 11:14 AM ET
    Heart Stent

    Leerink Swann, which specializes in healthcare equities research, is out with a couple of noteworthy surveys--one on the collateral damage to Merck and Schering-Plough's Vytorin this week and the other on drug-coated stents from Abbott Labs, Boston Scientific, Johnson & Johnson and Medtronic.

  • Pfizer Profit Doubles on Drug Sales, Lower Costs Wednesday, 23 Jul 2008 | 8:55 AM ET
    pfizer_hq.jpg

    Pfizer Wednesday said quarterly earnings more than doubled on higher sales of its prescription drugs and lower expenses, but its Chantix quit-smoking drug lost more than a third of its U.S. sales amid safety concerns.

  • Pharma: May Cause Nausea, Dry Mouth Tuesday, 22 Jul 2008 | 6:30 PM ET

    If only Merck could develop a treatment for this malady...

  • Stocks Rally to the Finish With Banks in the Lead Tuesday, 22 Jul 2008 | 4:59 PM ET

    Stocks surged in the final hour of trading as a sharp drop in oil prices and an analyst note prompted a late rally in financials. The Nasdaq eked out a gain but investors still punished select techs, including Apple and Texas instruments after the firms dispatched disappointing results.

  • Oil Boosts Stocks but Techs Weigh on Market Tuesday, 22 Jul 2008 | 3:34 PM ET

    Stocks advanced, buoyed by a sharp drop in oil prices, but technology stocks dragged on the market after disappointing earnings from Apple and Texas Instruments.

  • Merck And "Sex and the City" Strategy: Did It Work? Tuesday, 22 Jul 2008 | 2:38 PM ET
    Sex and The the City

    Recently I blogged about Merck advertising its cervical cancer vaccine Gardasil to a captive audience during trailers for the "Sex and the City" movie.